Skip to main content

Table 3 Anticipated Paediatric-equivalent dose comparable to adults with mitochondrial disease treated at 100 mg twice daily

From: A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms (“KHENERGYC”)

Population

Dose (mg) per administration (BID)

Neonates (0–28 days)

2

Infants (1–2.5 months)

4

Infants (2.5–12 months)

12

Toddlers (1–2 years)

23

Young Children (2–6 years)

33

Middle-Aged Children (6–12 Years)

55

Adolescents (12–17 years)

80